Leap Therapeutics Inc (NAS:LPTX)
$ 2.38 -0.09 (-3.64%) Market Cap: 91.07 Mil Enterprise Value: 36.73 Mil PE Ratio: 0 PB Ratio: 1.29 GF Score: 46/100

Leap Therapeutics Inc at Robert W Baird Global Healthcare Conference Transcript

Sep 13, 2023 / 07:10PM GMT
Release Date Price: $1.69 (-2.31%)
Joel Beatty
Baird - Analyst

Thank you for joining us for Baird's annual global healthcare conference. I'm Joel Beatty, one of Baird's small-cap biotech equity research analysts. And I'm really pleased to have with us Doug Onsi today from Leap Therapeutics.

Doug, thank you so much for joining us.

Doug Onsi
Leap Therapeutics, Inc. - President & CEO

It's a pleasure. Appreciate all the effort from everyone here at Baird to put the conference together.

Questions & Answers

Joel Beatty
Baird - Analyst

So to begin with, could you just provide an overview of Leap?

Doug Onsi
Leap Therapeutics, Inc. - President & CEO

Sure. So Leap Therapeutics is an oncology biomarker-focused drug development company. We're generating a pipeline of biomarker-targeted antibody therapies. And it's led by DKN-01, which is our monoclonal antibody that targets DKK1, which is a protein that's secreted by cancer cells and suppresses the ability of the immune system to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot